Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3585-3598

  Ryscavage, Patrick ^a   Kelly, Sean ^b   Li, Jonathan Z ^c   Richard Harrigan, P ^d   Taiwo, Babafemi ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; VIRUS RNA; DRUG COMBINATION;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; GENOTYPING TECHNIQUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; INFECTION RISK; LIMIT OF DETECTION; LOW LEVEL VIREMIA; MORBIDITY; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SEXUAL TRANSMISSION; VERY LOW LEVEL VIREMIA; VIRAL PHENOMENA AND FUNCTIONS; VIRAL REBOUND; VIREMIA; VIRUS DECAY; VIRUS DETECTION; VIRUS LOAD; VIRUS SHEDDING; VIRUS TRANSMISSION; BACTERIAL TRANSLOCATION; DRUG COMBINATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; PATHOLOGY; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BACTERIAL TRANSLOCATION; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; RISK FACTORS; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 84903206458     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00076-14     Document Type: Article

References (117)

1. European AIDS Clinical Society. 2013. European guidelines for treatment of HIV infected adults in Europe, version 6.1. European AIDS Clinical Society, Brussels, Belgium.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2013. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, Rockville, MD. http://aidsinfo.nih.gov/ contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
3. Writing Group, Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gilleece Y, Horne R, Johnson M, Khoo S, Leen C, Marshall N, Nelson M, Orkin C, Paton N, Phillips A, Post F, Pozniak A, Sabin C, Trevelion R, Ustianowski A, Walsh J, Waters L, Wilkins E, Winston A, Youle M. 2012. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. HIV Med. 13:S1-S85. http://dx.doi.org/10.1111/hiv.12119.
4. Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S. 2008. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir. Ther. 169:927-936.
5. Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, Miller V, Francioli P, Furrer H, Battegay M, Vernazza P, Bernasconi E, Günthard HF, Hirschel B, Phillips AN, Telenti A, Frankfurt HIV Clinic Cohort and Swiss HIV Cohort Study. 2002. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 16:1967-1969. http://dx.doi.org/10.1097/00002030-200209270-00017.
6. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 105:3879-3884. http://dx.doi.org/10.1073/pnas.0800050105. (Pubitemid 351723493)
7. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R, Liu S, Metcalf JA, Rehm C, Brun SC, Hanna GJ, Kempf DJ, Coffin JM, Mellors JW. 2007. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 3:e46. http://dx.doi.org/10.1371/journal.ppat.0030046.
8. Roche Molecular Diagnostics. 2013. Timeline of PCR and Roche. Roche Molecular Diagnostics, Pleasanton, CA. http://molecular.roche.com/About/pcr/ Pages/PCRTimeline.aspx.
9. Palmer S. 2013. Advances in detection and monitoring of plasma viremia in HIV-infected individuals receiving antiretroviral therapy. Curr. Opin. HIV AIDS 8:87-92. http://dx.doi.org/10.1097/COH.0b013e32835d80af.
10. Cobb BR, Vaks JE, Do T, Vilchez RA. 2011. Evolution in the sensitivity of quantitative HIV-1 viral load tests. J. Clin. Virol. 52:S77-S82. http://dx.doi.org/10.1016/j.jcv.2011.09.015.
11. Roche. 2013. Cobas AmpliPrep/Cobas TaqMan HIV-1 Test, v2.0. Roche Molecular Diagnostics, Pleasanton, CA. http://molecular.roche.com/assays/Pages/ COBASAmpliPrepCOBASTaqManHIV-1Testv20.aspx.
12. Abbott Molecular. 2013. Abbott RealTime HIV-1 package insert. Abbott Molecular, Abbott Park, IL. http://www.abbottmolecular.com/static/cms-workspace/ pdfs/US/51-602146R6.pdf.
13. Lima V, Harrigan R, Montaner JS. 2009. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the TaqMan assay in comparison to the Amplicor assay. J. Acquir. Immune Defic. Syndr. 51:3-6. http://dx.doi.org/10.1097/QAI.0b013e31819e721b.
14. Karasi JC, Dziezuk F, Quennery L, Förster S, Reischl U, Colucci G, Schoener D, Seguin-Devaux C, Schmit JC. 2011. High correlation between the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1, v2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes. J. Clin. Virol. 52:181-186. http://dx.doi.org/10.1016/j.jcv.2011.07.002.
15. Garrett NJ, Apea V, Nori A, Ushiro-Lumb I, Oliver AR, Baily G, Clark DA. 2012. Comparison of the rate and size of HIV-1 viral load blips with Roche Cobas TaqMan HIV-1 versions 1.0 and 2.0 and implications for patient management. J. Clin. Virol. 53:354-355. http://dx.doi.org/10.1016/j.jcv.2011.12.024.
16. Wirden M, Soulie C, Valantin M. 2011. Sequential HIV RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viremia, abstr 613. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 27 February to 2 March 2011.
17. Xu S, Song A, Nie J, Li X, Meng S, Zhang C, Wang Y. 2012. Comparison between the automated Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 assay and its version 1 and Nuclisens HIV-1 EasyQ version 2.0 assays when measuring diverse HIV-1 genotypes in China. J. Clin. Virol. 53:33-37. http://dx.doi.org/10.1016/j.jcv.2011.10.001.
18. Ruelle J, Debaisieux L, Vancutsem E, De Bel A, Delforge ML, Piérard D, Goubau P. 2012. HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability. BMC Infect. Dis. 12:100. http://dx.doi.org/10.1186/1471-2334-12-100.
19. Kran AB, Jonassen TØ, Sannes M, Jakobsen K, Lind A, Maeland A, Holberg-Petersen M. 2009. Overestimation of human immunodeficiency virus type 1 load caused by the presence of cells in plasma from plasma preparation tubes. J. Clin. Microbiol. 47:2170-2174. http://dx.doi.org/10.1128/JCM.00519-09.
20. Stosor V, Palella FJ, Jr, Berzins B, Till M, Leake A, Chmiel JS, Murphy RL. 2005. Transient viremia in HIV-infected patients and use of plasma preparation tubes. Clin. Infect. Dis. 41:1671-1674. http://dx.doi.org/10.1086/ 498025. (Pubitemid 41691608)
21. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126. http://dx.doi.org/10.1038/373123a0.
22. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191. http://dx.doi.org/10.1038/387188a0. (Pubitemid 27209434)
23. Sedaghat AR, Siliciano RF, Wilke CO. 2008. Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect. Dis. 8:1-14. http://dx.doi.org/10.1186/1471-2334-8-1.
24. Gilmore JB, Kelleher AD, Cooper DA, Murray JM. 2013. Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug action. PLoS Comput. Biol. 9:e1002971. http://dx.doi.org/ 10.1371/journal.pcbi.1002971.
25. Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acosta EP, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DR, AIDS Clinical Trials Group A5248 Team. 2013. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J. Infect. Dis. 208:884-891. http://dx.doi.org/10.1093/infdis/ jit272.
26. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, Dewar RL, Planta A, Liu S, Metcalf JA, Mellors JW, Coffin JM. 2003. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41:4531-4536. http://dx.doi.org/10.1128/JCM.41.10.4531-4536.2003. (Pubitemid 37259753)
27. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9:727-728. http://dx.doi.org/10.1038/nm880. (Pubitemid 36749221)
28. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517. http://dx.doi.org/10. 1038/8394. (Pubitemid 29220209)
29. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, Choi AL, Girling V, Ho T, Li P, Fujimoto K, Lampiris H, Hare CB, Pandori M, Haase AT, Günthard HF, Fischer M, Shergill AK, McQuaid K, Havlir DV, Wong JK. 2010. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J. Infect. Dis. 202:1553-1561. http://dx.doi.org/10.1086/656722.
30. García-Gascó P, Maida I, Blanco F, Barreiro P, Martín-Carbonero L, Vispo E, González-Lahoz J, Soriano V. 2008. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J. Antimicrob. Chemother. 61:699-704. http://dx.doi.org/10.1093/jac/dkm516.
31. Sklar PA, Ward DJ, Baker RK, Wood KC, Gafoor Z, Alzola CF, Moorman AC, Holmberg SD, HIV Outpatient Study (HOPS) Investigators. 2002. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS 16:2035-2041. http://dx.doi.org/10.1097/00002030-200210180-00008. (Pubitemid 35205267)
32. van Sighem A, Zhang S, Reiss P, Gras L, van der Ende M, Kroon F, Prins J, de Wolf F. 2008. Immunologic, virologic, and clinical consequences of episodes of transient viremia during suppressive combination antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 48:104-108. http://dx.doi.org/10.1097/QAI. 0b013e31816a1d4f. (Pubitemid 351600855)
33. Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, Cofrancesco J, Jr, Gallant JE, Quinn TC, Jackson B, Flexner C, Carson K, Ray S, Persaud D, Siliciano RF. 2005. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 293:817-829. http://dx.doi.org/10.1001/jama.293. 7.817. (Pubitemid 40250365)
34. Grennan JT, Loutfy MR, Su D, Harrigan PR, Cooper C, Klein M, Machouf N, Montaner JS, Rourke S, Tsoukas C, Hogg B, Raboud J, CANOC Collaboration. 2012. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J. Infect. Dis. 205:1230-1238. http://dx.doi.org/10.1093/infdis/jis104.
35. Gallien S, Delaugerre C, Charreau I, Braun J, Boulet T, Barrail-Tran A, de Castro N, Molina JM, Kuritzkes DR. 2011. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. AIDS 25:665-669. http://dx.doi.org/10.1097/QAD. 0b013e3283445834.
36. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Günthard HF, Richman DD, Wong JK. 2001. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 286:171-179. http://dx.doi.org/10.1001/jama.286.2.171.
37. Martinez V, Marcelin AG, Morini JP, Deleuze J, Krivine A, Gorin I, Yerly S, Perrin L, Peytavin G, Calvez V, Dupin N. 2005. HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor based regimen. AIDS 19:1065-1069. http://dx.doi.org/10.1097/01.aids.0000174453.55627. de. (Pubitemid 40961147)
38. Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG. 2005. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin. Infect. Dis. 41:1326-1332. http://dx.doi.org/10.1086/496985. (Pubitemid 41532678)
39. Mira JA, Macias J, Nogales C, Fernández-Rivera J, García-García JA, Ramos A, Pineda JA. 2002. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir. Ther. 7:251-256. (Pubitemid 36427129)
40. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. 2007. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J. Infect. Dis. 196:1773-1778. http://dx.doi.org/10.1086/523704. (Pubitemid 351411937)
41. Macias J, Palomares JC, Mira JA, Torres MJ, García-García JA, Rodríquez JM, Vergera S, Pineda JA. 2005. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J. Infect. 51:195-200. http://dx.doi.org/10.1016/j.jinf.2004.11.010.
42. Gianotti N, Galli L, Racca S, Salpietro S, Cossarini F, Spagnuolo V, Barda B, Canducci F, Clementi M, Lazzarin A, Castagna A. 2012. Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/ml. J. Antimicrob. Chemother. 67:213-217. http://dx.doi.org/10.1093/jac/dkr422.
43. Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, Gregis G, Quinzan G, Soavi L, Iannotti N, Malfatto E, Leone S. 2012. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J. Acquir. Immune Defic. Syndr. 60:473-482. http://dx.doi.org/10.1097/QAI.0b013e3182567a57.
44. Di Mascio M, Markowitz M, Louie M, Hurley A, Hogan C, Simon V, Follmann D, Ho DD, Perelson AS. 2004. Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection. J. Virol. 78:10566-10573. http://dx.doi.org/10.1128/JVI.78.19.10566-10573.2004. (Pubitemid 39258382)
45. Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, Kuritzkes DR, Eron JJ, Jr. 2011. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J. Infect. Dis. 204:515-520. http://dx.doi.org/10.1093/infdis/jir353.
46. Sungkanuparph S, Groger RK, Overton ET, Fraser VJ, Powderly WG. 2006. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med. 7:437-441. http://dx.doi.org/10.1111/j.1468-1293.2006.00403.x. (Pubitemid 44269810)
47. Havlir DV, Koelsch KK, Strain MC, Margot N, Lu B, Ignacio CC, Miller MD, Wong JK, Gilead 903 Study Team. 2005. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J. Infect. Dis. 191:1164-1168. http://dx.doi.org/10.1086/428588. (Pubitemid 40404376)
48. Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, Phillips AN, Geretti AM. 2012. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin. Infect. Dis. 54:724-732. http://dx.doi.org/10.1093/cid/cir936.
49. Charpentier C, Landman R, Laouénan C, Joly V, Hamet G, Damond F, Brun-Vézinet F, Mentré F, Descamps D, Yeni P. 2012. Persistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated factors and virological outcome. J. Antimicrob. Chemother. 67:2231-2235. http://dx.doi.org/10.1093/jac/dks191.
50. Henrich TJ, Wood BR, Kuritzkes DR. 2012. Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/ml. PLoS One 7:e50065. http://dx.doi.org/10.1371/journal.pone.0050065.
51. Widdrington J, Payne B, Medhi M, Valappil M, Schmid ML. 2011. The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART. J. Infect. 62:87-92. http://dx.doi.org/10. 1016/j.jinf.2010.11.001.
52. Álvarez-Estévez M, Chueca Porcuna N, Guillot Suay V, Peña Monge A, García García F, Muñoz Medina L, Vinuesa García D, Parra Ruiz J, Hernández-Quero J, García García F. 2013. Quantification of viral loads lower than 50 copies per milliliter by use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 test, version 2.0, can predict the likelihood of subsequent virological rebound to >50 copies per milliliter. J. Clin. Microbiol. 51:1555-1557. http://dx.doi.org/10.1128/JCM. 00100-13.
53. Easterbrook PJ, Ives N, Waters A, Mullen J, O'Shea S, Peters B, Gazzard BG. 2002. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to <400 copies/ml. AIDS 16:1521-1527. http://dx.doi.org/10.1097/00002030-200207260-00009. (Pubitemid 34804217)
54. Masquelier B, Pereira E, Peytavin G, Descamps D, Reynes J, Verdon R, Fleury H, Garraffo R, Chêne G, Raffi F, Brun-Vézinet F, APROCO/COPILOTE Study Group. 2005. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. J. Clin. Virol. 33:75-78. http://dx.doi.org/10.1016/j.jcv.2004.11. 012.
55. Miller LG, Golin CE, Liu H, Hays RD, Hua J, Wenger NS, Kaplan AH. 2004. No evidence of an association between transient HIV viremia ("blips") and lower adherence to the antiretroviral medication regimen. J. Infect. Dis. 189:1487-1496. http://dx.doi.org/10.1086/382895. (Pubitemid 38543599)
56. Jones LE, Perelson AS. 2007. Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 45:483-493. http://dx.doi.org/10.1097/QAI. 0b013e3180654836. (Pubitemid 47294919)
57. Boillat-Blanco N, Darling K, Schoni-Affolter F. 2012. Persistent low-level viraemia in HIV-1-infected patients: Swiss HIV Cohort Study, abstr H-1566. 52nd Interscience Conference on Antimicrobials and Chemotherapy. San Francisco, CA, 9 to 12 September 2012.
58. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. 2009. HIV monotherapy with rotinavir-boosted protease inhibitors: a systematic review. AIDS 23:279-291. http://dx.doi.org/10.1097/QAD.0b013e32831c54e5.
59. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Eron JJ, Jr, ACTG A5262 Team. 2011. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 25:2113-2122. http://dx.doi.org/10.1097/QAD.0b013e32834bbaa9.
60. Cologni G, Soavi L, Leone S, Valenti D, Callegaro A, Gregis G, Suter F, Maggiolo F. 2010. Low-level residual viremia and risk of virological failure. J. Int. AIDS Soc. 13:O5. http://dx.doi.org/10.1186/1758-2652-13-S4-O5.
61. Allavena C, Rodallec A, Sécher S, Reliquet V, Baffoin S, André-Garnier E, Billaud E, Raffi F, Ferré V. 2013. Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen. Med. Virol. 85:1878-1882. http://dx.doi.org/10.1002/ jmv.23679.
62. Kramer VG, Schader SM, Oliveira M, Colby-Germinario SP, Donahue DA, Singhroy DN, Tressler R, Sloan RD, Wainberg MA. 2012. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Antimicrob. Agents Chemother. 56:4154-4160. http://dx.doi.org/10.1128/AAC.00409-12.
63. Eisfeld C, Reichelt D, Evers S, Husstedt I. 2013. CSF penetration by antiretroviral drugs. CNS Drugs 27:31-55. http://dx.doi.org/10.1007/s40263-012- 0018-x.
64. Costiniuk CT, Kovacs C, Routy JP, Singer J, Gurunathan S, Sekaly RP, Angel JB. 2013. Short communication: human immunodeficiency virus rebound in blood and seminal plasma following discontinuation of antiretroviral therapy. AIDS Res. Hum. Retroviruses 29:266-269. http://dx.doi.org/10.1089/AID.2011.0343.
65. Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, Fauci AS. 2011. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J. Infect. Dis. 204:135-138. http://dx.doi.org/10.1093/infdis/jir208.
66. Bonora S, Nicastri E, Calcagno A, Gonzalez de Requena D, D'Ettorre G, Sarmati L, Palmisano L, Vullo V, Di Perri G, Andreoni M. 2009. Ultrasensitive assessment of residual HIV viremia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional study. J. Med. Virol. 81:400-405. http://dx.doi.org/10.1002/jmv.21405.
67. Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, Montaner JS. 2010. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J. Acquir. Immune Defic. Syndr. 55:460-465. http://dx.doi.org/10.1097/QAI.0b013e3181f2ac87.
68. Delaugerre C, Gallien S, Flandre P, Mathez D, Amarsy R, Ferret S, Timsit J, Molina JM, de Truchis P. 2012. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. PLoS One 7:e36673. http://dx.doi.org/10.1371/journal.pone.0036673.
69. Nettles RE, Kieffer TL, Simmons RP, Cofrancesco J, Jr, Moore RD, Gallant JE, Persaud D, Siliciano RF. 2004. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin. Infect. Dis. 39:1030-1037. http://dx.doi.org/10.1086/423388. (Pubitemid 39313462)
70. Mackie NE, Phillips AN, Kaye S, Booth C, Geretti AM. 2010. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J. Infect. Dis. 201:1303-1307. http://dx.doi.org/10.1086/651618.
71. Gonzalez-Serna A, Woods C, Li J, Harrigan R, Swenson L. 2013. Low-level HIV viremia and drug resistance, abstr 601. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, 3 to 6 March 2013.
72. Li JZ, Gallien S, Do TD, Martin JN, Deeks S, Kuritzkes DR, Hatano H. 2012. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob. Agents Chemother. 56:5998-6000. http://dx.doi.org/10.1128/AAC.01217- 12.
73. Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, Hunt PW, Hagos E, Nixon DF, Deeks SG. 2004. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 18:981-989. http://dx.doi.org/10.1097/00002030-200404300-00005. (Pubitemid 38591188)
74. Tobin NH, Learn GH, Holte SE, Wang Y, Melvin AJ, McKernan JL, Pawluk DM, Mohan KM, Lewis PF, Mullins JI, Frenkel LM. 2005. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J. Virol. 79:9625-9634. http://dx.doi.org/10.1128/JVI.79.15.9625-9634.2005. (Pubitemid 41022306)
75. Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sönnerborg A, Kaiser R, Codoñer FM, Van Laethem K, Bansi L, van de Vijver DA, Geretti AM, De Luca A, SEHERE Consortium. 2011. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J. Antimicrob. Chemother. 66:1886-1896. http://dx.doi.org/10. 1093/jac/dkr171.
76. Pellegrino D, Brígido L, Souza Cavalcanti J, Paul Ferreira J, Vidal J, Battaggia Gutierrez E. 2012. High frequency of genotypic resistance in HIV-1-infected patients on highly active antiretroviral therapy with persistent low level viremia. J. Int. AIDS Soc. 15:18173. http://dx.doi.org/10.7448/IAS.15. 6.18173.
77. von Wyl V, Yerly S, Böni J, Shah C, Cellerai C, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Ledergerber B, Günthard HF, Swiss HIV Cohort Study. 2012. Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clin. Infect. Dis. 54:131-140. http://dx.doi.org/10.1093/ cid/cir728.
78. Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H. 2013. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin. Infect. Dis. 57:1489-1496. http://dx.doi.org/10.1093/cid/cit529.
79. Swenson LC, Gonzalez-Serna A, Min JE, Woods CK, Li JZ, Harrigan PR. 2013. HIV drug resistance occurring during low level viremia is associated with subsequent virologic failure. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. Toronto, Canada, 4 to 8 June 2013.
80. Lo Re V, III, Gasink L, Kostman JR, Leonard D, Gross R. 2004. Natural history of patients with low-level HIV viremia on antiretroviral therapy. AIDS Patient Care STDs 18:436-442. http://dx.doi.org/10.1089/1087291041703692. (Pubitemid 39129274)
81. Corbeau P, Reynes J. 2011. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood 117:5582. http://dx.doi.org/10.1182/blood-2010-12-322453.
82. Neuhaus J, Jacobs DR, Jr, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD. 2010. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J. Infect. Dis. 201:1788-1795. http://dx.doi.org/10.1086/652749.
83. Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Lewin SR. 2011. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark. Med. 5:171-186. http://dx.doi.org/10.2217/bmm.11.15.
84. Klatt NR, Funderburg NT, Brenchley JM. 2013. Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 21:6-13. http://dx.doi.org/10.1016/j.tim.2012.09.001.
85. Sandler NG, Wand H, Rogue A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC, INSIGHT SMART Study Group. 2011. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203:780-790. http://dx.doi.org/10.1093/infdis/jiq118.
86. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD, INSIGHT SMART Study Group. 2008. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 5:e203. http://dx.doi.org/10.1371/journal.pmed. 0050203.
87. Zheng L, Bosch RJ, Chan ES, Read S, Kearney M, Margolis DM, Mellors JW, Eron JJ, Gandhi RT, AIDS Clinical Trials Group (ACTG) A5244 Team. 2013. Predictors of residual viremia in patients on long-term suppressive antiretroviral therapy. Antivir. Ther. 18:39-43. http://dx.doi.org/10.3851/ IMP2323.
88. Ostrowski SR, Katzenstein TL, Thim PT, Pedersen BK, Gerstoft J, Ullum H. 2005. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J. Infect. Dis. 191:348-357. http://dx.doi.org/10.1086/427340. (Pubitemid 40139759)
89. Taiwo B, Hunt PW, Gandhi RT, Ellingson A, McKenna M, Jacobson JM, Gripshover B, Bosch RJ. 2013. CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 63:101-104. http://dx.doi.org/10.1097/QAI. 0b013e3182895af4.
90. Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H. 2008. Residual viraemia in HIV-1-infected patients with plasma viral load
91. de Larrañaga GF, Petroni A, Deluchi G, Alonso BS, Benetucci JA. 2003. Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul. Fibrinolysis 14:15-18. http://dx.doi.org/10.1097/00001721- 200301000-00004.
92. Bastard JP, Soulié C, Fellahi S, Haïm-Boukobza S, Simon A, Katlama C, Calvez V, Marcelin AG, Capeau J. 2012. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir. Ther. 17:915-919. http://dx.doi.org/10.3851/IMP2093.
93. Reus S, Portilla J, Sánchez-Payá J, Giner L, Francés R, Such J, Boix V, Merino E, Gimeno A. 2013. Low-level HIV viremia is associated with microbial translocation and inflammation. J. Acquir. Immune Defic. Syndr. 62:129-134. http://dx.doi.org/10.1097/QAI.0b013e3182745ab0.
94. Eastburn A, Scherzer R, Zolopa AR, Benson C, Tracy R, Do T, Bacchetti P, Shlipak M, Grunfeld C, Tien PC. 2011. Association of low level viremia with inflammation and mortality in HIV-infected adults. PLoS One 6:e26320. http://dx.doi.org/10.1371/journal.pone.0026320.
95. Zhang S, van Sighem A, Kesselring A, Gras L, Smit C, Prins JM, Kauffmann R, Richter C, de Wolf F, Reiss P. 2012. Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 60:265-272. http://dx.doi.org/10.1097/QAI.0b013e318258c651.
96. Mugavero MJ, Napravnik S, Cole SR, Eron JJ, Lau B, Crane HM, Kitahata MM, Willig JH, Moore RD, Deeks SG, Saag MS, Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort Study. 2011. Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin. Infect. Dis. 53:927-935. http://dx.doi.org/10. 1093/cid/cir526.
97. El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. 2006. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355:2283-2296. http://dx.doi.org/10. 1056/NEJMoa062360.
98. Fiore J, Suligoi B, Saracino A, Di Stefano M, Bugarini R, Lepera A, Favia A, Monno L, Angarano G, Pastore G. 2003. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 17:2169-2176. http://dx.doi.org/10.1097/00002030-200310170-00004. (Pubitemid 37338890)
99. Vernazza P, Hirschel B, Bernasconi E, Flepp M. 2008. HIV-positive individuals not suffering from any other STD and adhering to an effective antiretroviral treatment do not transmit HIV sexually. Bull. Méd. Suisses 89:165-169. (In French.) http://dx.doi.org/10.1097/QAD.0b013e3282fd167c.
100. Loutfy MR, Wu W, Letchumanan M, Bondy L, Antoniou T, Margolese S, Zhang Y, Rueda S, McGee F, Peck R, Binder L, Allard P, Rourke SB, Rochon PA. 2013. Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PLoS One 8:e55747. http://dx.doi.org/10.1371/journal.pone.0055747.
101. Lambert-Niclot S, Tubiana R, Beaudoux C, Lefebvre G, Caby F, Bonmarchand M, Naouri M, Schubert B, Dommergues M, Calvez V, Flandre P, Poirot C, Marcelin AG. 2012. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey. AIDS 26:971-975. http://dx.doi.org/10.1097/QAD.0b013e328352ae09.
102. Cu-Uvin S, DeLong AK, Venkatesh KK, Hogan JW, Ingersoll J, Kurpewski J, De Pasquale MP, D'Aquila R, Caliendo AM. 2010. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 24:2489-2497. http://dx.doi.org/10.1097/QAD.0b013e32833e5043.
103. Kalichman SC, Di Berto G, Eaton L. 2008. Human immunodeficiency virus
104. Halfon P, Giorgetti C, Khiri H, Pénaranda G, Terriou P, Porcu-Buisson G, Chabert-Orsini V. 2010. Semen may harbor HIV despite effective HAART: another piece in the puzzle. PLoS One 5:e10569. http://dx.doi.org/10. 1371/journal.pone.0010569.
105. Ioannidis JP, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L, Korber BT, Mayaux MJ, Mofenson LM, Newell ML, Shapiro DE, Teglas JP, Wilfert CM. 2001. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J. Infect. Dis. 183:539. http://dx.doi.org/10.1086/318530.
106. Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, de Bruyn G, Kiarie J, Inambao M, Kilembe W, Farquhar C, Celum C, Partners in Prevention HSV/HIV Transmission Study Team. 2012. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J. Infect. Dis. 205:358-365. http://dx.doi.org/10.1093/infdis/jir747.
107. McConnell MJ, Mier-Mota J, Flor-Parra F, Martinez-Fernandez FJ, Lopez-Cortes LF, Viciana P, Fernandez-Cuenca F, Perez-Romero P. 2011. Improved viral suppression after treatment optimization in HIV-infected patients with persistent low-level viremia. J. Acquir. Immune Defic. Syndr. 58:446-449. http://dx.doi.org/10.1097/QAI.0b013e3182364513.
108. Di Mascio M, Markowitz M, Louie M, Hogan C, Hurley A, Chung C, Ho DD, Perelson AS. 2003. Viral blip dynamics during highly active antiretroviral therapy. J. Virol. 77:12165-12172. http://dx.doi.org/10.1128/JVI.77.22.12165- 12172.2003. (Pubitemid 37339869)
109. Hatano H, Delwart EL, Norris PJ, Lee TH, Neilands TB, Kelley CF, Hunt PW, Hoh R, Linnen JM, Martin JN, Busch MP, Deeks SG. 2010. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 24:2535-2539. http://dx.doi.org/10.1097/QAD.0b013e32833dba03.
110. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B, Palmer S, Medvik K, Lederman MM, Alatrakchi N, Jacobson JM, Wiegand A, Kearney M, Coffin JM, Mellors JW, Eron JJ, AIDS Clinical Trials Group A5244 Team. 2010. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 7:e1000321. http://dx.doi.org/10.1371/journal.pmed.1000321.
111. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, O'Shea A, Callender M, Spivak A, Brennan T, Kearney MF, Proschan MA, Mican JM, Rehm CA, Coffin JM, Mellors JW, Siliciano RF, Maldarelli F. 2009. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U S A. 106:9403-9408. http://dx.doi.org/10.1073/pnas.0903107106.
112. Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, Geretti AM, Kelleher P, Mackie N, Muir D, Murphy G, Orkin C, Post F, Rooney G, Sabin C, Sherr L, Smit E, Tong W, Ustianowski A, Valappil M, Walsh J, Williams M, Yirrell D, BHIVA Guidelines Subcommittee. 2012. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med. 13:1-44. http://dx.doi.org/10.1111/j.1468-1293.2011.00971.x.
113. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. 2008. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir. Ther. 13(Suppl 2):S1-S13.
114. Antinori A, Ammassari A, Torti C, Marconi P, Andreoni M, Angarano G, Bonora S, Castagna A, Cauda R, Clerici M, Monforte Ad, De Luca A, Di Perri G, Galli M, Girardi E, Gori A, Lazzarin A, Lo Caputo S, Mazzotta F, Montella F, Mussini C, Perno CF, Puoti M, Rizzardini G, Rusconi S, Vullo V, Carosi G. 2009. Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy. Infection 37:270-282. http://dx.doi.org/10.1007/s15010-008-8134-8.
115. Carosi G, Torti C, Andreoni M, Angarano G, Antinori A, Bonora S, Borderi M, Castagna A, Castelli F, Cauda R, Chiodo F, D'arminio-Monforte A, De Luca A, Di Perri G, Dianzani F, Filice G, Galli M, Lazzarin A, Maggiolo F, Maserati R, Mazzotta F, Moroni M, Perno CF, Vullo V, Italian HIV Guidelines Working Group. 2006. Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). J. Antimicrob. Chemother. 57:1055-1064. http://dx.doi.org/10.1093/jac/ dkl113.
116. Panel de Expertos de Gesida y Plan Nacional Sobre el Sida. 2012. Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012). Enferm. Infecc. Microbiol. Clin. 30:e1-89. (In Spanish.) http://dx.doi.org/10.1016/j.eimc.2012.03.006.
117. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. 2012. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308:387-402. http://dx.doi.org/10.1001/jama.2012.7961.